Exploration of lung mycobiome in the patients with non-small-cell lung cancer

被引:13
|
作者
Zhao, Yiming [1 ,2 ]
Yi, Junqi [1 ,3 ]
Xiang, Juanjuan [3 ,4 ,5 ]
Jia, Wei [6 ]
Chen, Anqi [1 ]
Chen, Liyu [2 ]
Zheng, Leliang [4 ,5 ]
Zhou, Wen [4 ,5 ]
Wu, Minghua [4 ,5 ]
Yu, Zheng [2 ]
Tang, Jingqun [1 ,3 ]
机构
[1] Cent South Univ, Xiangya Hosp 2, Dept Thorac Surg, Changsha, Hunan, Peoples R China
[2] Cent South Univ, Sch Basic Med Sci, Dept Microbiol, Changsha, Hunan, Peoples R China
[3] Hunan Key Lab Early Diag & Precise Treatment Lung, Changsha, Hunan, Peoples R China
[4] Cent South Univ, NHC Key Lab Carcinogenesis, Changsha, Hunan, Peoples R China
[5] Cent South Univ, Canc Res Inst, Sch Basic Med Sci, Chinese Minist Educ,Key Lab Carcinogenesis & Canc, Changsha, Hunan, Peoples R China
[6] Hong Kong Baptist Univ, Sch Chinese Med, Kowloon Tong, Peoples R China
基金
中国国家自然科学基金;
关键词
Non-small-cell lung cancer; Mycobiome; Alternaria arborescens; ACETALDEHYDE PRODUCTION; MICROBIOME; COMMUNITY; INFLAMMATION; INFECTIONS; IMMUNITY;
D O I
10.1186/s12866-023-02790-4
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
As the Human Microbiome Project (HMP) progresses, the relationship between microbes and human health has been receiving increasing attention. A growing number of reports support the correlation between cancer and microbes. However, most studies have focused on bacteria, rather than fungal communities. In this study, we studied the alteration in lung mycobiome in patients with non-small-cell lung cancer (NSCLC) using metagenomic sequencing and qPCR. The higher fungal diversity and more complex network were observed in the patients with NSCLC. In addition, Alternaria arborescens was found as the most relevant fungus to NSCLC, and the enrichment of it in cancerous tissue was also detected. This study proposes that the changes in fungal communities may be closely related to lung cancer, and provides insights into further exploration the relationship between lung cancer and fungi.
引用
收藏
页数:12
相关论文
共 50 条
  • [21] Immunotherapy of non-small-cell lung cancer
    Reinmuth, Niels
    Merk, Martina
    Duell, Thomas
    ONKOLOGE, 2021, 27 (02): : 179 - 190
  • [22] Pembrolizumab in Non-Small-Cell Lung Cancer
    Sorscher, Steven
    NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (10): : 996 - 997
  • [23] Avelumab in non-small-cell lung cancer
    Rosell, Rafael
    Karachaliou, Niki
    LANCET ONCOLOGY, 2018, 19 (11): : 1423 - 1424
  • [24] Radiochemotherapy in non-small-cell lung cancer
    Swartman, B.
    Hausmanns, J.
    Zwicker, F.
    Thomas, M.
    Herfarth, K.
    Heussel, C. P.
    MEDIZINISCHE KLINIK, 2011, 106 (03) : 212 - 217
  • [25] Non-small-cell lung cancer in the elderly
    Meriggi, F
    Zaniboni, A
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2006, 57 (02) : 183 - 190
  • [26] Cetuximab in non-small-cell lung cancer
    Carillio, Guido
    Montanino, Agnese
    Costanzo, Raffaele
    Sandomenico, Claudia
    Piccirillo, Maria Carmela
    Di Maio, Massimo
    Daniele, Gennaro
    Giordano, Pasqualina
    Bryce, Jane
    Normanno, Nicola
    Rocco, Gaetano
    Perrone, Francesco
    Morabito, Alessandro
    EXPERT REVIEW OF ANTICANCER THERAPY, 2012, 12 (02) : 163 - 175
  • [27] Immunotherapy for non-small-cell lung cancer
    Thomas, Anish
    Jakopovic, Marko
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2014, 14 (08) : 1061 - 1064
  • [28] LncRNAs in Non-Small-Cell Lung Cancer
    Ginn, Lucy
    Shi, Lei
    La Montagna, Manuela
    Garofalo, Michela
    NON-CODING RNA, 2020, 6 (03)
  • [29] Staging of Non-Small-Cell Lung Cancer
    Akhurst, Tim
    PET CLINICS, 2018, 13 (01) : 1 - +
  • [30] Erlotinib in non-small-cell lung cancer
    Gridelli, Cesare
    Rossi, Antonio
    Malone, Paolo
    Colantuoni, Giuseppe
    Del Gaizo, Filomena
    Ferrara, Carmine
    Nicolella, Dario
    Guerriero, Ciro
    EXPERT OPINION ON PHARMACOTHERAPY, 2007, 8 (15) : 2579 - 2592